Eaton Vance Management’s Pacira BioSciences PCRX Stock Holding History

Eaton Vance Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,073	Closed	-$65K	–	2454
2021 Q4	$65K	Buy	1,073 +570	+113%	+$31.4K	﹤0.01%	2001
2021 Q3	$0	Sell	503 -263	-34%	-$15.2K	﹤0.01%	2505
2021 Q2	$47K	Buy	766 +388	+103%	+$24.6K	﹤0.01%	2177
2021 Q1	$26K	Buy	+378	New	+$27K	﹤0.01%	1983
2018 Q2	–	Sell	-135,553	Closed	-$4.22M	–	1183
2018 Q1	$4.22M	Sell	135,553 -69,583	-34%	-$2.48M	0.01%	535
2017 Q4	$9.36M	Hold	205,136	–	–	0.02%	397
2017 Q3	$7.7M	Sell	205,136 -204,065	-50%	-$8.21M	0.02%	414
2017 Q2	$19.5M	Buy	+409,201	New	+$19M	0.05%	262

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Eaton Vance Management's PCRX Position: Q1 2022 in Review

Eaton Vance Management sold out of Pacira BioSciences (PCRX) in Q1 2022, closing a stake of 1,073 shares — an estimated $65K sold.

Eaton Vance Management first reported a position in PCRX in Q2 2017 and held it in 8 quarters. The position peaked at $19.5M in Q2 2017. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

Eaton Vance Management reported no remaining Pacira BioSciences position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 1,073 Pacira BioSciences shares in Q1 2022, an estimated $65K.
Eaton Vance Management first reported a position in Pacira BioSciences in Q2 2017 and held it in 8 quarters.
Eaton Vance Management's Pacira BioSciences position peaked at $19.5M in Q2 2017.
301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.